Tetra Bio-Pharma in Process of Filing Patent Application Exceeding its Data Protection Initial Assumption for its PPP001

World News: . []

ORLEANS, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- (“” or the “”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it is in process of filing a patent application for its PPP001 drug product.  Tetra’s research has led to a significant discovery that allows for patent protection.

“This patent application, if granted, would provide Tetra with full protection of its PPP001 prescription drug product.  This will put PPP001 in the same category as any other innovative prescription drug,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We recognize the inherent value of our intellectual property and the necessity to seek appropriate patents, to the extent possible, to protect our shareholders' investments in the Company.”

For more information visit: 

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

More news and information about Tetra Bio-Pharma Inc

Published By:

Globe Newswire: 11:30 GMT Thursday 6th December 2018

Published: .

Search for other references to "tetra" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us